Moxifloxacin + Prednisolone AcetateThird Party Manufacturing in India

Moxifloxacin + Prednisolone Acetate eye drops combine two active ingredients that work through distinct mechanisms to treat ocular inflammation and infection. Moxifloxacin, a fourth-generation fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. This dual-target mechanism provides broad-spectrum bactericidal activity against both Gram-positive and Gram-negative ocular pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Its potency against fluoroquinolone-resistant strains is enhanced by the simultaneous inhibition of both target enzymes.

Prednisolone Acetate is a corticosteroid that suppresses the inflammatory response by binding to glucocorticoid receptors within target cells. This binding triggers the synthesis of lipocortin, which inhibits phospholipase A2, reducing the release of arachidonic acid from membrane phospholipids. This action decreases the production of prostaglandins, leukotrienes, and other inflammatory mediators. Prednisolone also stabilizes lysosomal membranes, reduces capillary permeability, and inhibits leukocyte migration to the site of inflammation. The acetate ester formulation enhances corneal penetration, ensuring rapid delivery of the steroid to the anterior chamber of the eye.

Together, this combination provides both infection control and inflammation suppression in a single ophthalmic formulation, reducing the need for separate drops and improving patient compliance in post-surgical and traumatic ocular conditions.

Therapeutic Uses

Moxifloxacin + Prednisolone Acetate eye drops are prescribed for the treatment of:

• Post-operative Ocular Inflammation and Infection Prevention: Used routinely after cataract surgery, refractive surgery, and other ophthalmic surgical procedures to prevent bacterial endophthalmitis while controlling surgically-induced inflammation.
• Bacterial Conjunctivitis with Severe Inflammation: Effective for cases of bacterial conjunctivitis accompanied by significant inflammatory response where both antibiotic and corticosteroid therapy are warranted.
• Keratitis and Corneal Ulcers: Used in bacterial keratitis where both infection control and inflammation suppression are needed to prevent corneal scarring and vision loss.
• Blepharoconjunctivitis: Treats inflammation of the eyelid margins and conjunctiva when bacterial infection is present or suspected.
• Ocular Trauma: Manages inflammation and prevents secondary bacterial infection following corneal abrasions, foreign body injuries, and other ocular surface trauma.

Why Manufacturers Choose Moxifloxacin + Prednisolone Eye Drops

This combination has become the standard of care in ophthalmic post-surgical management, replacing older regimens of separate antibiotic and steroid drops. The convenience of a single combination product improves patient adherence and reduces drop administration errors. As cataract surgery volumes continue to rise globally, demand for this combination remains consistently high. Indian manufacturers with WHO-GMP certified ophthalmic manufacturing lines can produce this formulation in sterile multidose and unit-dose formats for both domestic and export markets.

This makes Moxifloxacin + Prednisolone Acetate eye drops one of the most sought-after ophthalmic combination products for third party manufacturing in India, with consistent demand from hospital supply chains, PCD franchise operators, and export-oriented pharmaceutical companies.